The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease
Open accessAbstract
Advances in the understanding of the cellular and molecular basis of hepatic fibrogenesis over the past 2 decades have allowed the emergence of a field dedicated to anti-fibrotic therapy. The liver responds to injury by wound healing and subsequently, fibrosis. This response is after essentially all kinds of injury (whether virus, alcohol, or other) and ultimately leads to cirrhosis in some patients. The observation that any of several types of liver diseases and their injury result in cirrhosis suggests a common pathogenesis. It is now recognized that a population or populations of effector cells play a critical role in the fibrogenic process. A classic effector cell, the hepatic stellate cell, is one of the most important fibrogenic cells in the liver. This cell undergoes a transformation during injury, termed “activation”. The activation process is complex, but one of its most prominent features is the synthesis of large amounts of extracellular matrix, resulting in deposition of scar or fibrous tissue. Thus, the hepatic stellate cell and/or other fibrogenic cell types have been a therapeutic target. It is further noteworthy that the fibrogenic process is dynamic and that even advanced fibrosis is reversible. The best anti-fibrotic therapy is elimination of the underlying disease process. For example, elimination of hepatitis B or C virus can lead to reversal of fibrosis. In situations in which treating the underlying process is not possible, specific anti-fibrotic therapy would be highly desirable. To date, many specific anti-fibrotic treatments have been tried, but none have succeeded yet. Nonetheless, because of the importance of fibrosis, the field of anti-fibrotic compounds is rapidly growing. This review will emphasize mechanisms underlying fibrogenesis as they relate to putative anti-fibrotic therapy, and will review current and potential future anti-fibrotic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727
Peroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Hammel, P., Couvelard, A., O'Toole, D., Ratouis, A., Sauvanet, A., Fléjou, J. F., Degott, C., Belghiti, J., Bernades, P., Valla, D., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102083440604 · Cited by 427
Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver
Benyon, R., Iredale, J., Goddard, S., Winwood, P., & Arthur, M. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8608892 · Cited by 353
Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310284200 · Cited by 320
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis
Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290603 · Cited by 209
Inhibition of Rat Hepatic Lipocyte Activation in Culture by Interferon–γ
Rockey, D. C., Maher, J. J., Jarnagin, W. R., Gabbiani, G., & Friedman, S. L. (1992) · Hepatology · doi:10.1002/hep.1840160325 · Cited by 179
Self-citation
Cited by
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.052 · Cited by 436
Lipid-based nanoparticle technologies for liver targeting
Böttger, R., Pauli, G., Chao, P.-H., AL Fayez, N., Hohenwarter, L., & Li, S.-D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.017 · Cited by 264
Mikulak, J., Bruni, E., Oriolo, F., Di Vito, C., & Mavilio, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00946 · Cited by 145
Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis
Schon, H.-T., Bartneck, M., Borkham-Kamphorst, E., Nattermann, J., Lammers, T., Tacke, F., & Weiskirchen, R. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00033 · Cited by 97
Metadata
- Authors
- Rockey, D. C.
- Venue
- Clinics in Liver Disease
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 12
- Issue
- 4
- Pages
- 939-962
- ISSN
- 1089-3261 (ISSN-L)
- OpenAlex
- W1986259247
- Cited by
- 163
- References
- 12
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease. https://app.cochat.ai/papers/10.1016/j.cld.2008.07.011
- The paper
- Rockey, D. C. (2008). Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease. Clinics in Liver Disease. https://doi.org/10.1016/j.cld.2008.07.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.